Q1 2027 Aarti Pharmalabs Ltd Earnings Call Transcript
Key Points
- Aarti Pharmalabs Ltd (BOM:543748) reported a strong Q1 FY27 with revenue up 42% YoY to Rs 535 crore and PAT up 49% YoY to Rs 71 crore.
- The Xanthine Derivatives segment achieved its highest-ever quarterly sales, contributing 57% of turnover, with a 25% volume growth YoY.
- The company completed debottlenecking of its steroid block at the US FDA-approved Tarapur site, increasing steroidal capacity by 33%.
- New xanthine derivative capacity has been commercialized, with plans to reach 80%+ capacity utilization by FY28, targeting a 20-25% global market share.
- The CDMO/CMO segment is expanding with 57 active projects (37 commercial), and a new Rs 149 crore dedicated block at Atali is expected to support the Rs 1,000 crore revenue goal.
- Management guided for a 40-50% growth in CDMO/CMO revenue for FY27, with a strong second-half skew expected.
- The company maintains a healthy EBITDA margin guidance of 22-25% for the full year, supported by a favorable product mix and cost optimization initiatives.
- Structural changes in China (removal of export rebates and production quotas) are expected to improve Xanthine pricing and margins sustainably.
- The API and Intermediates business is expected to recover to Rs 170-190 crore quarterly run-rate, aided by debottlenecking and new launches in anti-cancer and lifestyle products.
- The company has a strong R&D infrastructure with over 250 scientists across three centers, enhancing capabilities in CDMO and process intensification.
- Aarti Pharmalabs Ltd (BOM:543748) faces pricing pressures in existing API molecules, which may limit revenue growth in this segment.
- Xanthine realizations are expected to decline from peak levels as raw material prices normalize, impacting top-line growth in the near term.
- The company's CDMO/CMO revenue is heavily skewed towards the second half of the fiscal year, leading to lumpy quarterly performance.
- New capacity additions (Atali and Xanthine) will start incurring expenses in Q2 FY27, potentially impacting margins before full ramp-up.
- The API and Intermediates segment saw a revenue dip in Q1 due to a planned shutdown for debottlenecking, affecting quarterly performance.
- The company faces intense competition from Chinese producers in the Xanthine market, which could pressure pricing and market share.
- Raw material price volatility, exacerbated by the West Asia crisis, creates uncertainty in input costs and margin stability.
- The company's top 10 API products account for 60-70% of sales, indicating high concentration risk in this segment.
- CDMO/CMO gross margins are expected to remain in the 60-65% range, lower than peers due to a focus on manufacturing rather than early-stage research.
- The company's revenue guidance for Xanthine (Rs 900-1,100 crore) is broad, reflecting uncertainty in price normalization and demand.
Ladies and gentlemen, good day and welcome to the RT Pharma Labs Limited Q1 FY27 Earnings Conference Call hosted by 361 Capital Market Private Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. ( Operators Instructions )
This conference is being recorded. I now hand the conference over to Shuli Mehta from 361 Capital Market Private Limited.
Thank you and over to you.
Good afternoon everyone. On behalf of 361 Capital, we welcome you all to Q1 FY27 earnings conference call of RT Pharma Labs Limited.
From the management side, we have with us Mr. Rashesh Gogri, Chairman, and Mr. Piush Lakhani, Chief Financial Officer. I would now hand over the conference call to Rashesh Sir for his opening remarks, post which we will open the session for Q&A.
Thank you and over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
